Effect of Riocigaut on Migraine Attack Induction in People With Migraine

Inclusion Criteria: * A history of migraine without aura for ≥ 12 months according to the classification criteria of the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria. * An estimated average of between 1-5 migraine attacks per month. * Ability to provide written informed consent and receive participant privacy and rights information prior to initiation of any study-specific activities. * Male or female participants aged 18-45 years at screening. * No migraine preventive treatment at screening or during study conduction. * Non-smokers Exclusion Criteria: * Any current or previous history of other primary or secondary headache disorder(s) apart from tension type headache ≤ 5 days per month. * Lack of ability to differentiate migraine from other headaches * Headache within 24 hours before any study related procedures (Provocation Day 1 and Provocation Day 2) - Subjects are however allowed to be re-booked for provocation days according to allowed timelines. * Any daily medication apart from contraceptives. * Use of any antihypertensive, nitrates or nitric oxide donors or phosphodiesterase inhibitors, CYP3A4 and P-glycoprotein inhibitors, HIV-proteaseinhibitors, ciclosporin A or CYP1A1-inhibitors, antacida and acid-neutreulizing agents (such as aluminium-/magnesiumhydroxid), CYP3A4-inductors (such as bosentan, phenytoin, carbamazepin, phenobarbital and herbal remedies with perikon). * Intake of any pro necessitate medication later than 4 times plasma half-life for the specific drug before study start. * Women of child-bearing potential not currently using safe contraceptives. Women of child-bearing potential does not include hysterectomized women and women who have been in menopause for at least 2 years. Safe contraceptives include either IUD, birth control pills, surgical sterilization of the woman, depositary gestagen, barrier prevention or sexual abstinence. * Pregnant or breastfeeding women * Positive pregnancy urine screening on screening day or provocation days. * A medical history or clinical signs of * Hypertension (systolic blood pressure \>150mmHg and/or diastolic blood pressure \>100mmHg) * Hypotension (systolic blood pressure \<100mmHg and/or diastolic blood pressure \<50mmHg) * Electrocardiogram (ECG) with any clinically significant abnormalities at screening determined by the investigator, including but not limited to, prolonged PQ or QTc interval, signs of arrythmias, ischemia or left/right ventricle dysfunction/hypertrophy. * A medical history or clinical signs of pulmo-/cardiovascular disease including cerebrovascular disease. * A family history of severe cardiac disease. * A medical history or clinical signs of clinically significant psychiatric illness per investigator opinion. * The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior. * A medical history or clinical signs of substance or alcohol abuse * A medical history or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion. * Any history of hypersensitivity to riociguat. * Subjects who do not want information about crucial pathological findings during the study * Subject likely to not be available to complete all protocol-required study visits or procedures, and/or comply with all required study procedures to the best of the subject and study investigator's knowledge.